Ensysce Biosciences (NASDAQ:ENSC) Posts Quarterly Earnings Results, Beats Estimates By $0.37 EPS

Ensysce Biosciences (NASDAQ:ENSC) issued its quarterly earnings data on Tuesday. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.37, Zacks reports. Ensysce Biosciences had a negative return on equity of 559.68% and a negative net margin of 179.26%. The business had revenue of $3.42 million during the quarter, compared to analyst estimates of $0.25 million.

Ensysce Biosciences Stock Up 6.7 %

ENSC traded up $0.05 during trading on Wednesday, hitting $0.72. The company had a trading volume of 16,759,744 shares, compared to its average volume of 8,588,834. The firm’s 50-day moving average price is $0.36 and its 200 day moving average price is $0.45. The company has a market capitalization of $6.35 million, a PE ratio of -0.38 and a beta of 0.63. Ensysce Biosciences has a one year low of $0.14 and a one year high of $2.06.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.